Longeveron Inc Ordinary Shares - Class A LGVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron to Participate in Three Longevity/Aging Investment Conferences
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Longeveron Announces 1-for-10 Reverse Stock Split
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Trading Information
- Previous Close Price
- $1.71
- Day Range
- $1.70–1.70
- 52-Week Range
- $1.32–12.20
- Bid/Ask
- $1.65 / $1.78
- Shares Outstanding
- 3.19M
- Market Cap
- $5.58M
- Volume/Avg
- 1,237 / 106,531
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.48
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 38
- Website
- https://www.longeveron.com
Valuation
Metric | LGVN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.52 |
Price/Sales | 3.48 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | LGVN |
|---|---|
Quick Ratio | 2.35 |
Current Ratio | 2.63 |
Interest Coverage | — |
Quick Ratio
LGVN
Profitability
Metric | LGVN |
|---|---|
Return on Assets (Normalized) | −137.52% |
Return on Equity (Normalized) | −199.18% |
Return on Invested Capital (Normalized) | −184.75% |
Return on Assets
LGVN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|w<fX@>p | LOCK|V&<f | $138B | |||
| Moderna Inc MRNA | LOCK|MDLs?<v | LOCK|S^Q | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|j^^!!w@ | LOCK|$Wx# | $93B | |||
| argenx SE ADR ARGX | LOCK|!b!LdTG | LOCK|h% | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|s^qdF%q | LOCK|Z>> | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|#&B%CW$ | LOCK|><<q | $30B | |||
| Incyte Corp INCY | LOCK|b!$X^? | LOCK|gp | $24B | |||
| BioNTech SE ADR BNTX | LOCK|S#@WGM& | LOCK|pZ | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|G?<jMK | LOCK|Ws@^$ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|$W?!wR | LOCK|f> | $15B |
United States